Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics' stock price has been impacted by several events in the past six months. Positive Phase 1 results for OV329 led to a stock price surge and increased analyst price targets. A $60 million private placement was announced to extend the company's cash runway into 2029. The company's Q4 2025 earnings reflected better-than-expected results, contributing to positive market sentiment. Several analysts have reiterated or upgraded their ratings and increased price targets for OVID. The failure of its partnered drug soticlestat in a Phase 3 trial had previously impacted Ovid's stock. Ovid Therapeutics announced planned leadership succession and reported business updates and third-quarter 2025 financial results, and Dr. Petra Kaufmann was appointed as Chief Medical Officer.

As a biopharmaceutical company with product candidates still in clinical development, Ovid Therapeutics, Inc. does not currently experience demand seasonality for its products or services. The company's revenue is not driven by seasonal consumer purchasing patterns. Stock price seasonality relates to investor behavior and market trends rather than the demand for pharmaceutical products.

Ovid Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule medicines for rare neurological disorders, particularly epilepsies and seizure-related conditions. The company aims to address brain conditions caused by excess neural excitability. Its major product candidates include OV329, a GABA-aminotransferase inhibitor in Phase 1 trials; OV4071, an oral direct activator of KCC2 in Phase 1 trials; and a broader library of KCC2 direct activators. Ovid previously had a significant financial interest in soticlestat, but its partnered development faced setbacks.

Ovid Therapeutics Inc. is headquartered in New York, NY, United States. Its clinical development activities extend internationally, including regulatory clearance in Australia for its KCC2 modulator OV4071 to enter Phase 1 clinical evaluation.

Ovid Therapeutics has maintained a generally positive brand reputation over the past year, particularly among analysts. The company has received a consensus "Buy" rating from analysts. Positive Phase 1 results for OV329 have significantly bolstered confidence in the company's lead asset. The strategic $60 million private placement and encouraging Q4 2025 financials have also contributed to a positive market sentiment. The company's focus has shifted to its internal pipeline, particularly OV329 and the KCC2 activators, which analysts view favorably.

Ovid Therapeutics Inc. has a mixed ownership structure. Institutional investors hold approximately 29.56% to 40.99% of the company's stock. Retail investors hold approximately 48% to 49.23% of the company's stock. Insiders own about 9.79% of the company's stock, with Peter Kolchinsky owning the most shares. Public companies own approximately 6.7% of Ovid Therapeutics.